VAC 3S

Drug Profile

VAC 3S

Alternative Names: VAC3S

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Assistance Publique Hopitaux de Paris; INSERM; Universite Pierre et Marie Curie
  • Developer InnaVirVax
  • Class AIDS vaccines
  • Mechanism of Action HIV envelope protein gp41 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 24 Aug 2015 InnaVirVax completes enrolment in its phase I/IIa trial in HIV-1 infections in France (NCT02390466)
  • 24 Aug 2015 InnaVirVax completes enrolment in its phase II trial for HIV infections in France, Germany and Spain (NCT02041247)
  • 01 Apr 2015 InnaVirVax initiates enrolment in a phase I/IIa trial in HIV-1 infections in France (NCT02390466)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top